歌禮製藥-B:二零二三年年報
Jefferies: Goley Pharmaceuticals made significant progress in the HK$3.8 target pipeline
On April 18, 2024, Jefferies released a research report stating that Glory Pharmaceuticals currently focuses on the application of ASC41 and ASC40 in NASH indications, and is awaiting the disclosure of the mid-term results of the ASC40 phase III RGBM trial in the second half of the year. ASC41 showed positive results in mid-phase II data for NASH treatment. It has similar properties to lametirol, which has been approved by the FDA, and has shown significant advantages in reducing liver fat. ASC40 has also had positive results in clinical trials for F2/F3 NASH and acne. Furthermore, Golie Pharmaceuticals decided to end
Hong Kong Stock Announcement Nuggets | China Overseas Development: The cumulative contract property sales of China's overseas affiliates in the first three months were about RMB 60.206 billion, down 28% year on year
China Overseas Development (00688): The cumulative contract property sales volume of China's overseas affiliated companies in the first three months was about 60.206 billion yuan, down 28% year on year; Vanke Enterprise (02202) achieved contract sales of 57.98 billion yuan in the first quarter, a decrease of 42.81% year on year
Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus
Ascletis Pharma (HKG:1672) has decided not to proceed with further clinical trials of its farnesoid X receptor (FXR) agonist ASC42 for primary biliary cholangitis (PBC) indication, according to a fili
Kerry Pharmaceutical-B (01672.HK) Announces Strategic Decision on Farnesol X Receptor (FXR) agonist ASC42
On April 3, Gelonghui Pharmaceutical-B (01672.HK) announced a strategic decision on the farnesol X receptor (FXR) agonist ASC42. After thorough analysis of the ASC42 phase II clinical trial (ClinicAlt rials.gov: NCT05190523) data for primary biliary cholangitis (PBC), the company made a strategic decision not to continue clinical trials with ASC42 for PBC. The decision was based on efficacy and safety data from the 12-week phase II study, which included three ASC42 active treatment groups (5
Goli Pharmaceutical-B (01672) announced its 2023 annual results, with revenue of about 56.6 million yuan, an increase of 4.6% over the previous year
Goli Pharmaceutical-B (01672) announced the results for the year ended December 31, 2023. The Group's revenue increased from 2...
Goli Pharmaceutical-B (01672.HK) annual loss reduced to 145 million yuan
Gelonghui, March 25 | Goli Pharmaceutical-B (01672.HK) announced that for the year ended December 31, 2023, the company's revenue increased 4.6% from approximately RMB 54.1 million in the previous year to approximately RMB 56.6 million. The Group's total revenue (including revenue and other revenue and revenue) increased by 45.2% from approximately RMB 166.1 million in the previous year to approximately RMB 241.2 million. The Group's loss for the year decreased from RMB 314.8 million in the previous year to RMB 144.7 million in the same year, mainly due to (i) the increase in product sales revenue
ASCLETIS-B: ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Hong Kong Stock Announcement Nuggets | SF Express Tongcheng expects net profit from continuing operations to be no less than 60 million yuan in 2023
ESR's subsidiary interests in the proposed sale of ARA's private equity business are expected to achieve revenue of about 50 million US dollars; Glory Pharmaceutical-B announced that it will present the final results of the Phase II study of the FASN inhibitor ASC40 to treat acne at the 2024 American Academy of Dermatology (AAD) annual meeting
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
HANGZHOU and SHAOXING, China, March 11, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-
Cully Pharmaceutical-B (01672) announced that it will present the final results of the FASN inhibitor ASC40 to treat acne phase II at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Cully Pharmaceutical-B (01672) issued an announcement. The board of directors announced the 2024 US Skin to be held in San Diego, USA...
Goli Pharmaceutical-B cancelled 32.63 million shares repurchased on March 5
Goli Pharmaceutical-B (01672) issued an announcement to cancel 32.63 million repurchased shares on March 5, 2024.
Announcement Highlights | NIO's Q4 revenue increased 6.5% year on year to 17.103 billion yuan; Great Wall Motor's February sales increased 4.12% year on year
China Electric Power's combined total electricity sales volume in January was 10.3482 million megawatt-hours, an increase of 41.15% over the previous year; Shanghai Pharmaceutical: Norepinephrine bitartrate injection passed the generic drug consistency evaluation.
Goli Pharmaceutical-B (01672) cancelled 32.63 million shares repurchased on March 5
Goli Pharmaceutical-B (01672) issued an announcement to cancel 32.63 million shares and repurchase them on March 5, 2024...
Guojin Securities: Chronic Hepatitis B Cure Track has broad potential market space and continues to recommend companies that deploy long-acting interferons and related innovative drugs
The chronic hepatitis B cure track is one of the tracks that the trip continues to be optimistic about and recommended. Clinical cure for chronic hepatitis B has now entered a new stage from early exploration to international recognition to rapid and in-depth development.
Goley Pharmaceutical-B (01672.HK) plans to hold a board meeting on March 25 to approve annual results
On February 23, Ge Longhui Pharmaceutical-B (01672.HK) issued an announcement. The board of directors meeting will be held on March 25, 2024 (Monday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider recommending payment of a final dividend (if any).
ASCLETIS-B: NOTICE OF BOARD MEETING
Goli Pharmaceutical-B (01672.HK) spent HK$908,000 to buy back 480,000 shares on February 22
On February 22, Gelonghui Pharmaceutical-B (01672.HK) announced that on February 22, it spent HK$908,000 to buy back 480,000 shares at a price of HK$1.9-1.87 per share.
Goli Pharmaceutical-B (01672) spent HK$1.498 million to buy back 800,000 shares on February 21
Goli Pharmaceutical-B (01672) announced that on February 21, 2024, the company spent 1.498 million...
Goli Pharmaceutical-B (01672.HK) spent HK$452,600 to buy back 246,000 shares on February 19
On February 19, Gelonghui Pharmaceutical-B (01672.HK) announced that on February 19, it spent HK$452,600 to repurchase 246,000 shares at a price of HK$1.84 per share.
No Data